Drug intelligence / Profile preview

Myo-404

Development stage: Preclinical
Lead developer: MitoRx
Modality: Small Molecules
Administration: Oral

Overview

Myo-404 is an orally administered small molecule mitochondrial metabolism modulator under development by MitoRx Therapeutics. It is specifically designed to treat obesity and broader cardiometabolic diseases by targeting mitochondrial pathways to restore metabolic health. Unlike traditional weight-loss medications that primarily target appetite through the central nervous system or gut hormones, Myo-404 aims to directly influence cellular energy expenditure and metabolic efficiency. It is currently in the early stages of development as part of MitoRx's pipeline of mitochondrial-targeted therapeutics, which also includes an injectable program, Myo-006.

Targets

Mitochondrial persulfide/sulfide-signaling machinery

Beyond the preview

Go deeper on Myo-404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myo-404.

Explore the full profile